FRACTURE RISK IN WOMEN ≥65 YEARS WITH ONCE-MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE EVALUATION OF IBANDRONATE EFFICACY (VIBE) DATABASE STUDY

被引：0
|
作者：
Silverman, S. [1 ]
Poston, S. [2 ]
Blumentals, W. [3 ]
Reginster, J. -Y. [4 ]
机构：
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Beverly Hills, CA USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
[3] Roche, Nutley, NJ USA
[4] Univ Liege, Bone & Cartilage Metab Unit, Liege, Belgium
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：153 / 153
页数：1
相关论文
共 34 条
  • [1] Fracture Risk in Women Aged 65 Years or Older with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Analyses From the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.
    Silverman, S. L.
    Blumentals, W. A.
    Poston, S. A.
    Harris, S. T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S465 - S465
  • [2] Fracture Risk with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Primary and Sensitivity Analyses from the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.
    Harris, S. T.
    Blumentals, W. A.
    Poston, S. A.
    Silverman, S. L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S346 - S346
  • [3] Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study
    Harris, S. T.
    Reginster, J. -Y.
    Harley, C.
    Blumentals, W. A.
    Poston, S. A.
    Barr, C. E.
    Silverman, S. L.
    BONE, 2009, 44 (05) : 758 - 765
  • [4] FRACTURE RISK IN WOMEN TREATED WITH MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE VIBE DATABASE STUDY, EXCLUDING 35MG ALENDRONATE, OSTEOPENIA AND CORTICOSTEROIDS
    Cooper, C.
    Poston, S.
    Blumentals, W.
    Harris, S.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 151 - 152
  • [5] EFFICACY OF ONCE-MONTHLY ORAL BISPHOSPHONATES (IBANDRONATE AND RISEDRONATE) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
    Epstein, S.
    McCloskey, E.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 146 - 146
  • [6] Tolerability of once-monthly ibandronate across different age groups of women switched from once-weekly bisphosphonates
    Binkley, N.
    Martens, M. G.
    Kohles, J. D.
    Civitelli, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S450 - S450
  • [7] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [8] Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
    Miller, Paul D.
    Epstein, Sol
    Sedarati, Farhad
    Reginster, Jean-Yves
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 207 - 213
  • [9] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [10] Women treated with once-monthly Ibandronate demonstrate improved persistence after 3 months vs weekly bisphosphonates.
    Silverman, Stuart L.
    Harris, Steven T.
    Derman, Richard
    Barr, Charles E.
    Margolis, Jay
    Amonkar, Mayur M.
    Chesnut, Charles H., III
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S584 - S585
1234